Eli Lilly did not specify when sales of the drug would begin in China, or how many doses would be sold, according to Reuters. The drugmaker did not immediately respond to Investopedia 's request ...

Eli Lilly said in a social media post Friday its weight loss drug tirzepatide had received approval from Chinese regulators, further intensifying competition with its Danish rival Novo Nordisk in ...

The Chinese drug regulator, the National Medical Products Administration (NMPA), has approved Eli Lilly’s (NYSE:LLY) weight loss therapy, tirzepatide, for long-term weight management, the ...

You've heard about the likes of Ozempic, Wegovy and Mounjaro, jabs which a growing number of people are taking in an attempt ...

In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...

Some analysts expect Zepound, the U.S. firm's weight-loss drug with the same active ingredient, will be approved in China this year or in the first half of 2025.

After being granted a fast-tracked designation for weight loss by the Food and Drug Administration in October 2022, it’s believed diabetes drug Mounjaro will be approved for weight loss some ...

An experimental drug from Eli Lilly helped patients with obesity lose an average of 24% of their body weight over 48 weeks on the highest dose in a mid-stage study, the most weight loss seen yet ...

The drug, called Mounjaro for diabetes, will be called Zepbound for weight loss, according to a news release from the FDA. Made by Eli Lilly, it’s part of a new class of drugs that includes ...

Tirzepatide is the active ingredient in Lilly’s injectable diabetes drug Mounjaro and weight-loss drug Zepbound. Mounjaro previously was approved in China for diabetes treatment.

Wegovy, the weight-loss drug developed by Novo Nordisk, was approved for sale in China, opening up a new frontier for the Danish pharmaceutical company. The firm’s stock reached a record high ...

Blockbuster obesity drug Wegovy has been approved in China, opening the door for maker Novo Nordisk to begin selling it in the world's second-largest economy, where the appetite for similar ...